Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?

Affiliations

Comment

Chuanli Ren et al. J Clin Oncol. 2018.

. 2018 Aug 1;36(22):2353-2354.

doi: 10.1200/JCO.2018.78.1401. Epub 2018 Jun 12.

¹ Chuanli Ren, Chongxu Han, Daxin Wang, and Hui Chen, Clinical Medical College of Yangzhou University, Yangzhou, China.

No abstract available

Comment in

Reply to C. Ren et al.
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon-Carrera A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Heller G, et al. J Clin Oncol. 2018 Aug 1;36(22):2354-2356. doi: 10.1200/JCO.2018.78.2672. Epub 2018 Jun 12. J Clin Oncol. 2018. PMID: 29894273 No abstract available.
Reply to C. Ren et al.
Antonarakis ES. Antonarakis ES. J Clin Oncol. 2018 Aug 1;36(22):2356-2357. doi: 10.1200/JCO.2018.78.2680. Epub 2018 Jun 12. J Clin Oncol. 2018. PMID: 29894276 No abstract available.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Heller G, et al. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. J Clin Oncol. 2018. PMID: 29272162 Free PMC article.